Medical advances helping lift the fog of depression
Women are twice as likely than men to develop depression. New treatments are in the works.
The Miami Herald
By Lidia Dinkova
June 12, 2012
About 20 years ago, Sue gave the impression that she was the poster college girl. She was pretty, slim, in a sorority, and frequented bars and parties. But beneath that surface was a woman in her 20s struggling with depression, a condition that she has lived with until recently…Sue is hardly an isolated case. Worldwide, women are twice as likely to develop depression than men, said Dr. Charles Nemeroff, chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine. In the U.S. alone, one in five women will have a major depressive episode in their life. After puberty, women are more likely to get depression than men. Particularly risky phases are after childbirth, commonly known as postpartum depression, and during menopause. “Not any single one of these factors may be the reason why women may be more vulnerable. But when you put them together, they probably conspire to increase the risk,” Nemeroff said. The options: Vagus nerve stimulation, repetitive transcranial magnetic stimulation and deep brain stimulation are options available for patients who have not responded to other treatments, Nemeroff said. The vagus nerve stimulation treatment was originally approved by the Food and Drug Administration in 1997 for the treatment of epilepsy. In 2005, the FDA approved it for depression in cases where patients were not responsive to other treatments. A battery-powered generator similar to a pacemaker is implanted in the chest. A wire connected to the generator travels to the vagus nerve in the neck, where it sends electrical impulses to mood centers in the brain. The FDA approved repetitive transcranial magnetic stimulation in 2008. An electromagnet is placed on the scalp and magnetic pulses are sent from outside the skull to a small surface area of the brain. This type of treatment will soon be an option for patients at UM.
Deep brain stimulation has not been FDA approved for the treatment of depression but it has been approved for Parkinson’s disease and obsessive-compulsive disorder. It is offered to UM patients on a case-by-case basis. A hole is drilled in the skull and minuscule electrodes are lowered through a catheter into the brain area that affects mood. A generator is implanted under the chest skin to control the amount of brain stimulation. Only about 150 depression patients in the world have been treated with deep brain stimulation, Nemeroff said.
A year ago, the FDA approved Viibryd, a drug that increases serotonin levels in the brain by stimulating the brain’s serotonin receptors. Serotonin is a chemical produced by the body that allows brain cells and other nervous system cells to communicate with each other. Low serotonin levels have been linked to depression. Studies also are under way in which patients are given ketamine intravenously, a drug originally used as a tranquilizer by veterinarians. The FDA has not approved ketamine for treating depression. “It’s a whole new avenue of investigation,” Nemeroff said…
Ah, yes… the fog of depression… right up there with the heartbreak of psoriasis… thanks to DSM-5, clinical depression is being dumbed down to a bad hair day.
Honest to Pete, I don’t know how the guy sleeps at night. We’re going to suggest drilling holes in the skulls of depressed 20-something females? It’s a hard time of life…that transition to adulthood…getting a job, living independently, supporting yourself, managing relationships. pressure about marriage, biological clock ticking….it was a very challenging stage of life and many people need help navigating it….but drilling a hole in your skull??? Hard to see how that would help.
One more thing: does Nemeroff know any real humans? Like real people with real problems and challenges. Sure doesn’t sound to me like he does.
“Have been linked to” is getting to be a really bad joke.
Not to mention how relentlessly women have been targeted as a market for psychiatric ailments by pharmapsychiatry. The reason? Men aren’t such great customers because they don’t like the sexual dysfunction brought on by medications.
A 20-year-old with existential angst? Surely that can be a DSM-5 diagnosis.
Disgrace upon disgrace. Nemeroff has no shame. He must be looking for p.r. opportunities to rehab his image.
On May 30 the Miami Herald published a story about Grassely questioning NIH over the PTSD grant to Nemeroff. Then this piece of “journalism” appeared about two weeks later. Most likely, the PR department at the U of Miami fed a story to a willing Herald reporter.
Tom,
Excellent point! They sure showed us…